Clinical Trial Update: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population [Phase 3]

View source ↗

Summary

A Phase 3 trial of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) in 4- to 6-year-old children has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Epidemic Meningitis | Phase 3 | Status: COMPLETED